Histotripsy is a non-invasive cancer treatment that uses ultrasound to break up tumors in the body. It uses controlled sound waves to create micro-bubbles to destroy the targeted diseased tissue, eliminating the use of radiation, chemotherapy and surgical incisions. It was developed over 20 years ago by Michigan Engineering researchers in collaboration with clinicians @MichiganMedicine and the U-M Rogel Cancer Center, and later brought to clinical use by Minneapolis based company HistoSonics.
After successful clinical trials in Europe and the United States, where HistoSonics Edison Platform was used to treat patients with metastatic liver tumors, the Food and Drug Administration has approved the use of histotripsy in hospitals worldwide. With the FDA approval, Histosonics can now sell the Edison Platform to hospitals, giving liver cancer patients a non-invasive treatment option.
This research was led by: Zhen Xu, professor of biomedical engineering
#cancer
#cancertreatment
#cancersupport
#cancersurvivor
#cancerawareness
#cancertalk
#cancerwarrior
#cancerfighter
#cancerhope
#cancerfree
#curecancer
#cancerresearch
#cancerclinicaltrials
#breastcancer
#lungcancer
#prostatecancer
#coloncancer
#leukemia
#lymphoma
#melanoma
#ovariancancer
#pancreaticcancer
#renalcancer
#skincancer
#thyroidcancer
#chemotherapy
#radiationtherapy
#surgery
#immunotherapy
#targetedtherapy
#clinicaltrials
#supportivescare
#palliativecare
#canceradvocate
#cancercaregiver
#cancercommunity
#cancerjourney
#cancerlife
#cancerlove
#cancerpositive
#cancerstrong
#cancertogether
#cancerfreeworld
#endcancer
#cancerresearchfunding
